Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Endocrine 47NET 27Gastrointestinal 26Thoracic 8Sarcoma 6Head & Neck 6CNS 6Dermatologic 5Genitourinary 3Breast 3Other solid neoplasm 2Other hematologic neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Prostatic Neoplasms 5016Carcinoma, Renal Cell 1574Urinary Bladder Neoplasms 1279Kidney Neoplasms 723Breast Neoplasms 642Neoplasms 628Carcinoma, Transitional Cell 487Neoplasm Metastasis 468Carcinoma, Non-Small-Cell Lung 467Melanoma 421Ovarian Neoplasms 399Colorectal Neoplasms 370Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 231Stomach Neoplasms 226Uterine Cervical Neoplasms 223Testicular Neoplasms 215Non-Muscle Invasive Bladder Neoplasms 214Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 187Colonic Neoplasms 167Carcinoma, Hepatocellular 165Esophageal Neoplasms 164Endometrial Neoplasms 164Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 128Neuroblastoma 127Small Cell Lung Carcinoma 125

Interventions

Sunitinib 2pentetreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Adenoma, Islet Cell × Genitourinary × Clear all
NCT05800106 2023-04-10

A Bioequivalence Study of Sunitinib Malate Capsules.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Completed
24 enrolled
GastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Adenoma, Islet Cell, Gastrointestinal Stromal Tumors

NCT00428220 2019-06-27

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Pfizer

Phase NA Completed
223 enrolled 8 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Somatostatinoma, Thyroid Neoplasms, Gastrointestinal Stromal Tumors

NCT00002947 2014-07-02

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Yale University

Phase 1 Terminated
35 enrolled
CNSDermatologicEndocrineGenitourinaryHead & NeckThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Central Nervous System Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡